Investment & M&A transaction comps
Probiotics Investment & M&A Transaction Comps
Explore investment and M&A transactions tagged probiotics. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.
Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.
- Reviewed transactions
- 13
- With value data
- 6
- With revenue multiples
- 6
- Transaction years
- 2017–2026
Sortable transaction comps
Probiotics transaction table
Rows with reported value
7 / 13
Acquisition EV, USD
USD 14B
Investment EV, USD
-
Median EV / revenue
6.0x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
13 shown of 13 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately, and a financing without a reported valuation shows its amount raised, not an EV.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| BIO-CAT Enzymes & Microbials Control | 2026-07-31 | Lallemand Inc. | Undisclosed | Undisclosed | - | - | United States | Confirmed 1 source | ||
| Lactobio Control | 2023-12-04 | L’Oréal | Undisclosed Undisclosed | Undisclosed | - | - | Denmark | Confirmed 1 source | ||
| Adare Biome Control (100%) | 2023-04-19 | dsm-firmenich AG | EUR 275M Enterprise Value | 301 | - | 18.0x | France & Global | Confirmed 1 source | ||
| Chr. Hansen Holding Control | 2022-12-12 | Novozymes | USD 12B | 12,300 | 9.3x | 26.2x | Denmark | Confirmed 1 source | ||
| Bucklebury Control | 2022-09-01 | Haleon | Undisclosed Undisclosed | Undisclosed | - | - | United Kingdom | Confirmed 1 source | ||
| Microbiome Labs Control | 2021-01-06 | Novozymes | USD 125M Consideration | 125 | 3.1x | 6.0x | United States | Confirmed 1 source | ||
| Jennewein Biotechnologie GmbH Control (100%) | 2020-09-22 | Chr. Hansen Holding A/S | EUR 310M Enterprise Value | 367 | 6.2x | - | Germany & Global | Confirmed 1 source | ||
| PrecisionBiotics Group Limited Control (100%) | 2020-06-25 | Novozymes | DKK 600M Enterprise Value | 90 | 6.0x | - | Cork, Ireland | Estimated 1 source | ||
| UAS Laboratories LLC Control | 2020-06-09 | Chr. Hansen Holding A/S | USD 530M Enterprise Value | 530 | 6.2x | - | United States | Confirmed 1 source | ||
| Probiotics International Control | 2018-07-02 | ADM | USD 243M Consideration | 243 | 5.6x | 21.2x | United Kingdom | Estimated 2 sources | ||
| BioCare Copenhagen Control (20%) | 2017-12-22 | DSM | Undisclosed Undisclosed | Undisclosed | - | - | Denmark | Confirmed 1 source | ||
| Ganeden Control | 2017-10-11 | Kerry Group | Undisclosed | Undisclosed | 6.0x | 20.0x | - | Confirmed 1 source | ||
| Agro Biosciences, Inc. Control | - | Church & Dwight | Undisclosed | Undisclosed | - | - | - | Confirmed 15 sources |
Explore related tags
Continue to the full transaction history for each tag.
Explore buyers & investors
Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.